Sanofi to acquire Translate Bio shares for $38, representing equity value of $3.2 billion
MLex Summary: France-based Sanofi has agreed to acquire US-based Translate Bio, a clinical-stage messenger RNA therapeutics company, for $38 a share, representing a $3.2 billion equity value. The deal is expected...To view the full article, register now.
Already a subscriber? Click here to view full article